FDG PET and PET/CT in the Management of Pediatric Lymphoma Patients

Gang Cheng; Sabah Servaes; Abass Alavi; Hongming Zhuang

doi:10.1016/j.cpet.2009.04.004

FDG PET and PET/CT in the Management of Pediatric Lymphoma Patients

PET Clin. 2008 Oct;3(4):621-34. doi: 10.1016/j.cpet.2009.04.004. Epub 2009 Jul 25.

Authors

Gang Cheng¹, Sabah Servaes¹, Abass Alavi¹, Hongming Zhuang²

Affiliations

¹ Department of Radiology, Division of Nuclear Medicine, Children's Hospital of Pennsylvania, 34th and Civic Center Blvd, Philadelphia, PA 19104, USA.
² Department of Radiology, Division of Nuclear Medicine, Children's Hospital of Pennsylvania, 34th and Civic Center Blvd, Philadelphia, PA 19104, USA. Electronic address: zhuang@email.chop.edu.

PMID: 27156825
DOI: 10.1016/j.cpet.2009.04.004

Abstract

Fluorodeoxyglucose (FDG) PET has an ever-increasing role in the management of Hodgkin's and non-Hodgkin's lymphomas, which has been demonstrated in numerous studies in the adult population. In children and adolescents, however, only a limited number of studies have investigated the role of FDG PET in lymphoma. This article reviews the currently available literature on the clinical application of FDG PET in the management of childhood lymphoma. The authors believe that FDG PET (and especially PET/CT) is a valuable imaging modality in the initial diagnosis, response assessment, and post-therapy residual evaluation of Hodgkin's and FDG-avid non-Hodgkin's lymphomas in children and adolescents, and will have a significant impact on the clinical management of pediatric lymphoma.

Keywords: FDG; Lymphoma; PET; PET/CT; Pediatric.

Publication types

Review